Search results
Showing 1 to 15 of 1327 results for nice quality standards or clinical guidelines
Pulmonary artery pressure technologies for remote monitoring of chronic heart failure (HTG769)
Evidence-based recommendation on the routine use of pulmonary artery pressure technologies for remote monitoring of chronic heart failure.
How to use NICE guidance to reduce health inequalities in people experiencing cardiovascular disease (CVD).
Help make a difference on behalf of the people most affected by our recommendations on our voluntary and community sector forum.
Targeted-release budesonide for treating primary IgA nephropathy (TA1128)
Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.
How to use NICE guidance to reduce health inequalities during and after pregnancy.
Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.
Digital technologies to support self-management of COPD: early value assessment (HTG736)
Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.
"position":1,"item":{"@id":"/","name":"Home"}}]} Terms and conditions The NICE websites ("the websites") and all information contained...
Our recommendations on the use of highly specialised technologies are made by an independent advisory committee
Our recommendations on the use of highly specialised technologies are made by an independent advisory committee
Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.
Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.
Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.
Outside interests of the NICE board
Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.